Edition:
United Kingdom

Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

19.88USD
4:00pm GMT
Change (% chg)

$0.26 (+1.33%)
Prev Close
$19.62
Open
$19.67
Day's High
$20.13
Day's Low
$19.41
Volume
40,657
Avg. Vol
153,249
52-wk High
$23.01
52-wk Low
$9.35

Latest Key Developments (Source: Significant Developments)

Codexis Reports 2018 Fourth Quarter And Full Year Financial Results
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Codexis Inc ::CODEXIS REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.03.Q4 LOSS PER SHARE $0.01.Q4 REVENUE $16.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.7 MILLION.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.PRODUCT SALES ARE EXPECTED TO BE $26 MILLION TO $29 MILLION IN 2019.GROSS MARGIN ON PRODUCT SALES IS EXPECTED TO BE 48% TO 52% IN 2019.  Full Article

Codexis Announces Enzyme Supply Agreement With Kyorin Pharmaceutical For Overactive Bladder Drug Sold In Japan
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Codexis Inc ::CODEXIS ANNOUNCES ENZYME SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL FOR OVERACTIVE BLADDER DRUG SOLD IN JAPAN.CODEXIS INC - ANNOUNCES A MULTI-YEAR, EXCLUSIVE SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL CO., LTD..  Full Article

Codexis Q2 Loss Per Share $0.07
Wednesday, 8 Aug 2018 

Codexis Inc ::CODEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.02.Q2 LOSS PER SHARE $0.07.Q2 REVENUE $13.5 MILLION VERSUS I/B/E/S VIEW $11.6 MILLION.SEES FY 2018 REVENUE $60 MILLION TO $63 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.PHASE 1A CLINICAL TRIAL FOR CDX-6114 INITIATED.SEES FY PRODUCT REVENUE TO BE $25 MILLION TO $28 MILLION.  Full Article

Codexis Announces Proposed Public Offering Of Common Stock
Thursday, 5 Apr 2018 

April 6 (Reuters) - Codexis Inc ::CODEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Telemark Asset Management LLC reports 6.72 pct passive stake in Codexis ‍​as of Nov 10
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Codexis Inc :Telemark Asset Management LLC reports 6.72 percent passive stake in Codexis Inc ‍​as of November 10 - SEC Filing.  Full Article

Codexis Q3 non-gaap loss per share $0.17
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Codexis Inc ::Codexis reports financial results for the third quarter of 2017.Q3 non-gaap loss per share $0.17.Q3 loss per share $0.21.Sees FY 2017 revenue $50 million to $53 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Codexis Inc - ‍total revenues for Q3 of 2017 were $10.0 million compared with $14.9 million for q3 of 2016​.Codexis Inc - ‍gross margin on product sales is expected to be between 40% and 43% for 2017​.  Full Article

Codexis Inc, Nestlé Health Science enter strategic collaboration​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Codexis Inc :Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​.Codexis Inc - ‍Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success for deal​.Codexis Inc - deal ‍includes an option for global development of CDX-6114 for PKU​.Codexis Inc - ‍Codexis will be responsible for clinical development costs for CDX-6114 up to and including Phase 1 in healthy volunteers​.Codexis - after ‍phase 1, Nestlé health science will have option to obtain exclusive global license to CDX-6114.Codexis - after ‍Phase 1, Nestlé health science will be responsible for all future development and commercialization of CDX-6114​.  Full Article